Naval Daver, MD, is a hematologist-oncologist and physician-scientist specializing in leukemia. He is Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. His clinical practice centers on hematologic oncology, cellular and immune therapies, and precision oncology and early-phase clinical trials. His research interests include molecularly targeted therapies, immune-based therapeutics including monoclonal and bispecific antibodies and checkpoint inhibition, and translational trial design to overcome resistance. Achievements include the MD Anderson Faculty Scholar Award, chairing the Novartis Siremadlin Global Clinical Trial Steering Committee, leadership within the International Working Group for Acute Leukemia, and service on the editorial boards of the Journal of Hematology Oncology and Blood and Cancer Journal. He earned his medical degree from Grant Medical College and Sir J.J. Group of Hospitals in Mumbai and completed residency and a hematology-oncology fellowship at Baylor College of Medicine in Houston.
Professor
Medical School
2004
Residency
2005 – 2008
Fellowship
2004 – 2005